Cost-effectiveness analysis of intrathecal baclofen therapy in Japan.

Intrathecal baclofen (ITB) therapy was approved for health insurance coverage in 2005 for the treatment of patients whose spasticity could not be adequately controlled by conventional therapy, and is currently being used to treat around 300 patients nationwide in Japan. Various reports have examined the efficacy and safety of ITB therapy, but no report has evaluated the patient quality of life and medical costs in Japan. A cost-utility analysis of ITB was conducted by time period in six severely spastic patients admitted to our university hospital between 2005 and 2010 for ITB therapy. The average cost of ITB therapy per quality-adjusted life year (QALY; number of years survival in perfect health) 5 years after surgery was 1,554,428 yen, below the 6 million yen willingness-to-pay threshold for 1 QALY. This study shows that ITB therapy in Japan is an outstanding treatment in medicoeconomic terms.

[1]  Antigone S Papavasiliou,et al.  Management of motor problems in cerebral palsy: a critical update for the clinician. , 2009, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[2]  L. Saltuari,et al.  Cost-effectiveness Modeling of Intrathecal Baclofen Therapy Versus Other Interventions for Disabling Spasticity , 2009, Neurorehabilitation and neural repair.

[3]  B. Russman.  Continuous intrathecal baclofen infusion for intractable spastic cerebral palsy—is it worth it? , 2008, Nature Clinical Practice Neurology.

[4]  L. Matza,et al.  Cost-effectiveness of Intrathecal Baclofen Therapy for the Treatment of Severe Spasticity Associated With Cerebral Palsy , 2007, Journal of child neurology.

[5]  J. Lave,et al.  Willingness to Pay for a Quality-Adjusted Life Year: Implications for Societal Health Care Resource Allocation , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[7]  F. Sampson,et al.  Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. , 2002, Journal of neurosurgery.

[8]  E. Spatz,et al.  Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. , 1996, Journal of neurosurgery.

[9]  H. Dubo,et al.  Intrathecal Baclofen Therapy for Adults with Spinal Spasticity: Therapeutic Efficacy and Effect on Hospital Admissions , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  A S Detsky,et al.  Cost and Health Implications of Cholesterol Lowering , 1992, Circulation.

[11]  E. Nord,et al.  Methods for quality adjustment of life years. , 1992, Social science & medicine.

[12]  G. Torrance.  Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[13]  A. Williams.  Economics of coronary artery bypass grafting. , 1985, British medical journal.

[14]  A. Lloyd,et al.  Cost-Effectiveness Comparison of Tizanidine and Baclofen in the Management of Spasticity , 2012, PharmacoEconomics.

[15]  M. Hoving.  Intrathecal baclofen therapy in children with intractable spastic cerebral palsy : a Dutch national study , 2008 .

[16]  Y. Ohkusa,et al.  Research for Willingness to Pay for One QALY Gain , 2006 .

[17]  D. Benhamou,et al.  [Value of intrathecal baclofen in the treatment of severe tetanus in the tropical milieu]. , 2000, Medecine tropicale : revue du Corps de sante colonial.

[18]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .